急性早幼粒细胞白血病出血并发症的机制及治疗进展

[1]	Li J,Zhu H,Hu J,et al.Progress in the treatment of acute promyelocytic leukemia:optimization and obstruction[J].Int J Hematol,2014,100:38-50.
[2]	Breccia M,Coco F.Thrombo-hemorrhagic deaths in acute promyelocytic leukemia[J].Thromb Res,2014,133:S112-S116.
[3]	Levi M.Current understanding of disseminated intravascular coagulation[J].Br J Haematol,2004,124:567-576.
[4]	Breen KA,Grimwade D,Hunt BJ.The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia[J].Br J Haematol,2012,156:24-36.
[5]	Ikezoe T.Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia,and its treatment using recombinant human soluble thrombomodulin[J].Int J Hematol,2014,100:27-37.
[6]	Falanga A,Alessio MG,Donati MB,et al.A new procoagulant in acute leukemia[J].Blood,1988,71:870-875.
[7]	Choudhry A,Deloughery TG.Bleeding and thrombosis in acute promyelocytic leukemia[J].Am J Hematol,2012,87:596-603.
[8]	Yan J,Wang K,Dong L,et al.PML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association[J].Proc Natl Aca Sci U S A,2010,107:3716-3721.
[9]	Dombret H,Scrobohaci ML,Daniel MT,et al.In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL):effect of all-trans retinoic acid (ATRA) therapy[J].Leukemia,1995,9:19-24.
[10]	Sakata Y,Murakami T,Noro A,et al.The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia[J].Blood,1991,77:1949-1957.
[11]	Bennett B,Booth NA,Croll A,et al.The bleeding disorder in acute promyelocytic leukaemia:fibrinolysis due to u-PA rather than defibrination[J].Br J Haematol,1989,71:511-517.
[12]	Liu Y,Wang Z,Jiang M,et al.The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia[J].Leuk Res,2011,35:879-884.
[13]	Das R,Burke T,Plow EF.Histone H2B as a functionally important plasminogen receptor on macrophages[J].Blood,2007,110:3763-3772.
[14]	Hajjar KA,Acharya SS.Annexin II and regulation of cell surface fibrinolysis[J].Ann N Y Acad Sci,2000,902:265-271.
[15]	Kwaan HC,Rego EM.Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia[J].Semin Thromb Hemost,2010,36:917-924.
[16]	Griffin JD,Rambaldi A,Vellenga E,et al.Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors[J].Blood,1987,70:1218-1221.
[17]	Dittman WA,Majerus PW.Structure and function of thrombomodulin:a natural anticoagulant[J].Blood,1990,75:329-336.
[18]	Khan MM,Liu Y,Khan ME,et al.Upregulation of tissue factor in monocytes by cleaved high molecular weight kininogen is dependent on TNF-alpha and IL-1beta[J].Am J Physiol Heart Circ Physiol,2010,298:H652-H658.
[19]	Mondino A,Blasi F.uPA and uPAR in fibrinolysis,immunity and pathology[J].Trends Immunol,2004,25:450-455.
[20]	Menell JS,Cesarman GM,Jacovina AT,et al.Annexin II and bleeding in acute promyelocytic leukemia[J].N Engl J Med,1999,340:994-1004.
[21]	Yanada M,Matsushita T,Asou N,et al.Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia:incidence,risk factors,and influence on outcome[J].Eur J Haematol,2007,78:213-219.
[22]	Dally N,Hoffman R,Haddad N,et al.Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients[J].Thromb Res,2005,116:109-114.
[23]	Chang H,Kuo MC,Shih LY,et al.Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia[J].Eur J Haematol,2012,88:321-328.
[24]	Kim DY,Lee JH,Lee JH,et al.Significance of fibrinogen,D-dimer,and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia[J].Leuk Res,2011,35:152-158.
[25]	Ventura GJ,Hester JP,Dixon DO,et al.Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia[J].Hematol Pathol,1989,3:23-28.
[26]	de la Serna J,Montesinos P,Vellenga E,et al.Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin[J].Blood,2008,111:3395-3402.
[27]	Sawamura A,Hayakawa M,Gando S,et al.Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality[J].Thromb Res,2009,124:608-613.
[28]	Sanz MA,Grimwade D,Tallman MS,et al.Management of acute promyelocytic leukemia:recommendations from an expert panel on behalf of the European LeukemiaNet[J].Blood,2009,113:1875-1891.
[29]	Pisciotto PT,Benson K,Hume H,et al.Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients[J].Transfusion,1995,35:498-502.
[30]	Di Bona E,Awisati G,Castaman G,et al.Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia[J].Br J Haematol,2000,108:689-695.
[31]	Falanga A,Iacoviello L,Evangelista V,et al.Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid[J].Blood,1995,86:1072-1081.
[32]	Sanz MA,Tallman MS,Lo-Coco F.Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia[J].Blood,2005,105:3019-3025.
[33]	Dubois C,Schlageter MH,de Gentile A,et al.Modulation of IL-8,IL-1 beta,and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia[J].Leukemia,1994,8:1750-1757.
[34]	Tallman MS,Lefèbvre P,Baine RM,et al.Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia[J].J Thromb Haemost,2004,2:1341-1350.
[35]	Rashidi A,Riley M,Goldin T A,et al.Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia:final results of a multicentric study in the United States[J].Leuk Res,2014,38:1036-1040.
[36]	Altman JK,Rademaker A,Cull E,et al.Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death[J].Leuk Res,2013,37:1004-1009.
[37]	McClellan JS,Kohrt HE,Coutre S,et al.Treatment advances have not improved the early death rate in acute promyelocytic leukemia[J].Haematologica,2012,97:133-136.
[38]	Lehmann S,Ravn A,Carlsson L,et al.Continuing high early death rate in acute promyelocytic leukemia:a population-based report from the Swedish Adult Acute Leukemia Registry[J].Leukemia,2011,25:1128-1134.
[39]	Wassenaar T,Black J,Kahl B,et al.Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency:a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients[J].Hematol Oncol,2008,26:241-246.
[40]	Alimoghaddam K,Ghavamzadeh A,Jahani M.Use of Novoseven for arsenic trioxide-induced bleeding in PML[J].Am J Hematol,2006,81:720-720.
[41]	Zver S,Andoljsek D,Cernelc P.Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia[J].Eur J Haematol,2004,72:455-456.